skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

90 Total results for product and free and sample content found

Datamonitor Healthcare, Pink Sheet

Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?

Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?

The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.

Topic Drug Approval Standards FDA

Trialtrove

The Lost Trials of 2020

The Lost Trials of 2020

Disruption to clinical trials was a well-documented side effect of the COVID-19 pandemic, with trial sponsors and clinical sites dramatically scaling back activities in line with increased hospital burden, lockdown measures, and reduced patient mobility. 

Topic Coronavirus Clinical Trials Clinical Trials Blog BioPharmaceutical

Datamonitor Healthcare

Pharma Must Not Let Its COVID-19 Halo Slip

Pharma Must Not Let Its COVID-19 Halo Slip

Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.

Topic Coronavirus immuno-oncology BioPharmaceutical

Pharma 360

Pharma360: Improving the Speed to Insight

Pharma 360

Finding and organizing critical pharmaceutical and medtech data has long been a tedious task requiring hours spent gathering information from disparate sources. Pharma360 aims to change that.  

Topic Market Intelligence Outlook Medtech Combination Products Launches Platform Technologies Drug Development Landscape

Pharmaprojects

To infinity and beyond: how far can mRNA vaccine technology go?

 To infinity and beyond: how far can mRNA vaccine technology go?

With over 63 million confirmed cases and over 1.4 million deaths worldwide as of the start of December, the COVID-19 pandemic has certainly lit a fire under the pharmaceutical industry in the pursuit of therapeutics. In the process, with the recent emergency use authorisation in the UK for Pfizer and BioNTech’s BNT-162b2 vaccine, and the 94.5% efficacy reported by Moderna for its mRNA-1273 vaccine, a new technology has shot to the forefront: the mRNA vaccine.

Topic Diseases Drug Development Landscape Vaccines

Datamonitor Healthcare

mHealth and Research in Oncology

mHealth and Research in Oncology

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

Datamonitor Healthcare, Biomedtracker

Gene therapy manufacturers

Gene therapy manufacturers

Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

Biomedtracker, Datamonitor Healthcare

Deconstructing the KRAS+ market opportunity

Deconstructing the KRAS+ market opportunity

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic BioPharmaceutical Drug Review

Strategic Transactions

2019 IPOs Startup Firms Grab Nearly One-Third Of Total Proceeds

Medtech_Insight_CMS_Weighs_Merits_Of_New_Pass_Through_Payments_For_Aquabeam_System_Eluvia_Stents_In_OPPS_Proposal

Last year, a total of 67 biopharma and medtech companies completed initial public offerings (IPOs), raising for $8.55bn combined.

Topic Drug Pricing

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: